Recon: Senate report says AbbVie sheltered profits from US taxes; Merck in talks to acquire Seagen for $40B
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy